FindMyKOL
Clinical trialNCT03393468CompletedPhase 1Interventional

Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults

NCT03393468 is a phase 1 interventional trial sponsored by National Institute of Allergy and Infectious Diseases (NIAID). As of 21 Nov 2026, it is completed. It studies Dapivirine gel in HIV Infections. The registry lists an enrollment of 16 participants at 1 site in 1 country. The registry lists a start date of 10 May 2018 and a primary completion date of 3 Dec 2018.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03393468
FieldValue
Registry IDNCT03393468
StatusCompleted
PhasePhase 1
Study typeInterventional trial
Lead sponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Enrollment16
Registered sites1
Countries1
ConditionsHIV Infections
DrugsDapivirine gel
Start10 May 2018
Primary completion3 Dec 2018
Study completion3 Dec 2018
Last update posted25 Oct 2021

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the pharmacokinetics of dapivirine gel administered rectally to HIV-1 seronegative adults.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Pennsylvania, United States1 site
  • University of Pittsburgh Crs

    Pittsburgh

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 1 sitePA1New JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dapivirine gel
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03393468

Each answer restates registry values shown on this page.

What is NCT03393468?

NCT03393468 is a phase 1 interventional trial sponsored by National Institute of Allergy and Infectious Diseases (NIAID). It studies Dapivirine gel in HIV Infections.

Who leads NCT03393468?

The registry names Ken Ho, MD (study chair, University of Pittsburgh) as the overall official.

Where does NCT03393468 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03393468 study?

The registered drug and biological interventions are Dapivirine gel.

When did NCT03393468 end?

The registry lists a primary completion date of 3 Dec 2018 and a study completion date of 3 Dec 2018. The sponsor last updated the record on 25 Oct 2021.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.